Cargando…
The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models
Echistatin, a cyclic RGD peptide, which is an antagonist of α(v)β(3) integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model. A high-metastatic variant of human osteosarcoma, 143...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349968/ https://www.ncbi.nlm.nih.gov/pubmed/27894082 http://dx.doi.org/10.18632/oncotarget.13497 |
_version_ | 1782514572488343552 |
---|---|
author | Tome, Yasunori Kimura, Hiroaki Sugimoto, Naotoshi Tsuchiya, Hiroyuki Kanaya, Fuminori Bouvet, Michael Hoffman, Robert M. |
author_facet | Tome, Yasunori Kimura, Hiroaki Sugimoto, Naotoshi Tsuchiya, Hiroyuki Kanaya, Fuminori Bouvet, Michael Hoffman, Robert M. |
author_sort | Tome, Yasunori |
collection | PubMed |
description | Echistatin, a cyclic RGD peptide, which is an antagonist of α(v)β(3) integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model. A high-metastatic variant of human osteosarcoma, 143B-LM4, overexpressing α(v)β(3) integrin was used. Tumor angiogenesis by high-metastatic variant 143B-LM4 cells in the CAM was significantly inhibited by echistatin (P<0.05) as was overall growth. A doxorubicin (DOX)-echistatin combination inhibited orthotopic tumor growth compared to untreated control (P<0.01) or DOX alone (P<0.05) in nude mice. Tumor-bearing mice treated with the DOX-echistatin combination survived longer than those treated with DOX alone or control PBS (P<0.01 and P<0.01, respectively). Echistatin also inhibited experimental lung metastasis of 143B-LM4 cells in nude mice. These results suggest that DOX in combination with a disintegrin has potential to treat osteosarcoma and that α(v)β(3) integrin may be a target for osteosarcoma. |
format | Online Article Text |
id | pubmed-5349968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53499682017-04-06 The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models Tome, Yasunori Kimura, Hiroaki Sugimoto, Naotoshi Tsuchiya, Hiroyuki Kanaya, Fuminori Bouvet, Michael Hoffman, Robert M. Oncotarget Research Paper Echistatin, a cyclic RGD peptide, which is an antagonist of α(v)β(3) integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model. A high-metastatic variant of human osteosarcoma, 143B-LM4, overexpressing α(v)β(3) integrin was used. Tumor angiogenesis by high-metastatic variant 143B-LM4 cells in the CAM was significantly inhibited by echistatin (P<0.05) as was overall growth. A doxorubicin (DOX)-echistatin combination inhibited orthotopic tumor growth compared to untreated control (P<0.01) or DOX alone (P<0.05) in nude mice. Tumor-bearing mice treated with the DOX-echistatin combination survived longer than those treated with DOX alone or control PBS (P<0.01 and P<0.01, respectively). Echistatin also inhibited experimental lung metastasis of 143B-LM4 cells in nude mice. These results suggest that DOX in combination with a disintegrin has potential to treat osteosarcoma and that α(v)β(3) integrin may be a target for osteosarcoma. Impact Journals LLC 2016-11-22 /pmc/articles/PMC5349968/ /pubmed/27894082 http://dx.doi.org/10.18632/oncotarget.13497 Text en Copyright: © 2016 Tome et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Tome, Yasunori Kimura, Hiroaki Sugimoto, Naotoshi Tsuchiya, Hiroyuki Kanaya, Fuminori Bouvet, Michael Hoffman, Robert M. The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title | The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title_full | The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title_fullStr | The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title_full_unstemmed | The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title_short | The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
title_sort | disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α(v)β(3) integrin in chick embryo and nude mouse models |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349968/ https://www.ncbi.nlm.nih.gov/pubmed/27894082 http://dx.doi.org/10.18632/oncotarget.13497 |
work_keys_str_mv | AT tomeyasunori thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT kimurahiroaki thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT sugimotonaotoshi thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT tsuchiyahiroyuki thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT kanayafuminori thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT bouvetmichael thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT hoffmanrobertm thedisintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT tomeyasunori disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT kimurahiroaki disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT sugimotonaotoshi disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT tsuchiyahiroyuki disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT kanayafuminori disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT bouvetmichael disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels AT hoffmanrobertm disintegrinechistatinincombinationwithdoxorubicintargetshighmetastatichumanosteosarcomaoverexpressingavb3integrininchickembryoandnudemousemodels |